Kumar Neil, Chief Executive Officer of BridgeBio Pharma, has filed 155 Form 4 transactions across three companies, with every disclosed trade a sale. The total value of his open-market sales reached $65,056,417.78, and he has recorded zero purchases, zero acquisitions, and zero grants during the period covered. His recent activity, 19 sales in the last reporting window, shows no buying at all.
The bulk of Neil's selling has been in BBIO, the ticker for BridgeBio Pharma. His largest cluster of sales occurred on August 18 and 19, 2026, with values ranging from $8,565 to $1,421,513.50. On August 18 alone, he sold shares worth $2,889,993.53, and the next day added another $840,257.34. Earlier in June, he sold $2,142,333.34 on June 5 and $1,349,106.49 on June 4. A May 21 sale brought in $1,200,752.46. These are open-market sales, coded S, and they show a steady liquidation pattern over the past three months.
The August 16 filings include four option exercises coded M, each valued at $0, and one tax withholding event coded F for $2,893,886.82. These are mechanical or automatic transactions, not discretionary sales. The only other company in the recent data is BBOT, where a June 16 grant coded A carried a $0 value. Neil's total sell value of $65 million, with no offsetting purchases, makes his direction unambiguous. He is a seller, and the recent trades in BBIO, particularly the large August transactions, continue that trend.
AI-assisted summary